Precise science. Boundless impact. Meet Definium Therapeutics. Read Press Release

We measure progress by the lives we transform

Guided by precision and scientific rigor, we are harnessing the full therapeutic potential of psychedelic medicine to develop accessible treatments that unlock healing at scale

We lead with science

Everything we do is science-led and evidence-backed.

We start at the source

We are redefining what treatment success looks like by solving for root causes.

We set the right standard

We are redefining mental healthcare with transparency, trust, and responsibility.

We build with care

Science is personal. We are built on collaboration and care.

A man with short gray hair and a beard stands outdoors, facing away, looking at a landscape with grass, shrubs, and distant hills.

Redefining what treatment means for anxiety and depression

Millions living with anxiety and depression have been stuck with a status quo that, for too long, has simply not worked for them. There’s broad recognition that today’s treatments fall short of what patients need and that those who suffer are out of options.

From day one, we have been powered by a radical idea: treatments for anxiety and depression should bring real relief. Today, we are making that idea a reality. We are opening new routes for brain health by retracing LSD to its origins and unlocking its clinical promise as a transformative therapeutic. Our science is turning evidence into impact, serving as a catalyst that can help people renew their sense of self and reclaim more vibrant lives.

Clinical Trials
A person with hands clasped sits while another person writes on a clipboard, suggesting a conversation or counseling session.

Moving psychiatry forward – beyond better, into a boundless future

Fueled by our combined decades of expertise at the forefront of biotech, our vision is to drive healing at scale. Whether we are advancing new molecules or building new partnerships, we measure progress by the lives we transform.

DT120 ODT

DT120 orally disintegrating tablet (ODT) is our proprietary and pharmaceutically optimized formulation of lysergide (LSD) D-tartrate. DT120 ODT increases connections between areas of the brain that aren’t normally connected, enabling changes that could treat depression, anxiety, and other health disorders.

Learn More
Minimalist line drawing of a lightbulb with an orange diamond shape in the center.

DT402

DT402 is the R-enantiomer of MDMA (R(-)-MDMA), selected for its serotonergic properties. In preclinical studies, DT402 has shown promising prosocial effects with a potentially superior tolerability profile compared to both racemic MDMA and the S-enantiomer.1 DT402 is being developed to target the core symptoms of autism spectrum disorder, specifically addressing social communication challenges.

Learn More
A simple line drawing with three rectangles and one orange diamond arranged vertically, connected by lines, on a white background.

Making healing possible for those who need more than better

GAD is a chronic, debilitating disorder characterized by excessive anxiety and worry lasting for 6 months or more. Patients with GAD find it difficult to control the worry, often resulting in impairment in social, occupational, or other areas of functioning.2

A woman with long dark hair looks upward, illuminated by warm light against a dark background.

MDD is characterized by the presentation of five or more depressive symptoms, occurring for at least 2 weeks and can include feelings of worthlessness, fatigue, impaired social functioning, and recurrent thoughts of death.3

A person wearing glasses, a striped shirt, and an open button-down shirt stands in front of an orange corrugated metal wall, looking to the side.

Approximately 5.4M people in the U.S. live with ASD.4 There are no drugs approved to treat the core symptoms, which include communication and social interaction challenges.

A man with short dark hair and a beard looks to the side, sunlight partially illuminating his face. He is wearing a plaid shirt and appears to be indoors.

Adults in the U.S. living with GAD5

26M

Adults in the U.S. living with MDD5

41M

Adults in the U.S. living with ASD4

5.4M

Research & Development Pipeline

Our pipeline offers opportunities across diverse therapeutic areas and mechanisms of action.

Clinical trial progress chart showing two product candidates (DT120 ODT and DT402 RHX/MDMA) across indications and phases, marked by dots for each stage from preclinical to registration.
  1. Formerly known as MM120.
  2. Formerly known as MM402.
  3. Full trial details and clinicaltrials.gov links available on https://www.definiumtx.com/clinical-trials/.
  4. Studies in exploration and/or planning stage.

ODT: orally disintegrating tablet; R(-)-MDMA: rectus-3,4-methylenedioxymethamphetamine

Close-up of a person's face with warm sunlight casting shadows, showing detailed skin texture and focus on their eyes looking to the side.

Precise science.
Boundless impact.

Corporate Presentation
Contact Us
  1. “MM402 demonstrates better efficacy than S(+)-3,4-MDMA or (+/-)-MDMA in Fmr1 knockout mice, an animal model of autism spectrum disorder.” Presented at ECNP 2023. Data from “stranger” portion of “Duration in the arena” data.
  2. Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI International.
  3. APA. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth edition, text revision. ed. Washington, DC: American Psychiatric Association Publishing; 2022.
  4. Dietz PM, Rose CE, McArthur D, Maenner M. National and State Estimates of Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2020;50(12):4258-4266.
  5. Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI International and current U.S. Census data and internal company estimates.

The therapies we are investigating are not approved by the FDA or any other countries’ Health Authorities. This means their safety and efficacy are still being evaluated and have not been established.